1. Home
  2. Analysis
  3. Zofran
  4. Postmenopausal-haemorrhage

Zofran and Postmenopausal haemorrhage - a phase IV clinical study of FDA data

Summary:

Postmenopausal haemorrhage is reported as a side effect among people who take Zofran (ondansetron hydrochloride), especially for people who are 50-59 old, also take Percocet, and have Metastases to bone.

The phase IV clinical study analyzes which people have Postmenopausal haemorrhage when taking Zofran. It is created by eHealthMe based on reports of 93,713 people who have side effects when taking Zofran from the FDA, and is updated regularly.

What is Zofran?

Zofran has active ingredients of ondansetron hydrochloride. It is often used in nausea. eHealthMe is studying from 94,987 Zofran users. Check the latest studies of Zofran.

What is Postmenopausal haemorrhage?

Postmenopausal haemorrhage (post-menopausal bleeding) is found to be associated with 378 drugs and 331 conditions by eHealthMe. Check the latest studies of Postmenopausal haemorrhage.

On Jul, 20, 2026

93,713 people reported to have side effects when taking Zofran.
Among them, 21 people (0.02%) have Postmenopausal haemorrhage.

Could Zofran cause Postmenopausal haemorrhage?

Among these 21 people:

What is the age of people who have Postmenopausal haemorrhage when taking Zofran? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 9.09 %
  • 50-59: 72.73 %
  • 60+: 18.18 %

What are other drugs people take besides Zofran? *

  1. Zometa: 18 people, 85.71%
  2. Percocet: 18 people, 85.71%
  3. Atenolol: 15 people, 71.43%
  4. Aredia: 13 people, 61.90%
  5. Toradol: 13 people, 61.90%
  6. Synthroid: 13 people, 61.90%
  7. Dexamethasone: 12 people, 57.14%
  8. Oxycontin: 11 people, 52.38%
  9. Lasix: 10 people, 47.62%
  10. Nexium: 10 people, 47.62%

What are other side effects people have besides Postmenopausal haemorrhage? *

  1. Stress And Anxiety: 20 people, 95.24%
  2. Pain: 19 people, 90.48%
  3. Osteonecrosis Of Jaw (death of bone of jaw): 18 people, 85.71%
  4. Diarrhea: 15 people, 71.43%
  5. Sepsis (a severe blood infection that can lead to organ failure and death): 15 people, 71.43%
  6. Dehydration (dryness resulting from the removal of water): 15 people, 71.43%
  7. Back Pain: 15 people, 71.43%
  8. Dizziness: 14 people, 66.67%
  9. Osteoarthritis (a joint disease caused by cartilage loss in a joint): 13 people, 61.90%
  10. Deformity (disfigurement): 13 people, 61.90%

What are the existing conditions these people have? *

  1. Metastases To Bone (cancer spreads to bone): 9 people, 42.86%
  2. Breast Cancer: 6 people, 28.57%
  3. Neoplasm Malignant (cancer tumour): 5 people, 23.81%
  4. Pain: 2 people, 9.52%
  5. Multiple Myeloma (cancer of the plasma cells): 2 people, 9.52%
  6. Breast Cancer Stage Iv: 2 people, 9.52%
  7. Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 1 person, 4.76%
  8. Stress And Anxiety: 1 person, 4.76%
  9. Pain Exacerbated: 1 person, 4.76%
  10. Diabetes: 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Zofran and have Postmenopausal haemorrhage?

- Check whether Postmenopausal haemorrhage is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zofran:

Postmenopausal haemorrhage treatments and more:

How severe was Postmenopausal haemorrhage and when was it recovered:

Expand to all the drugs that have ingredients of ondansetron hydrochloride:

Sub-studies by age:

0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Zofran:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Postmenopausal haemorrhage:

Browse all the conditions that are associated with Postmenopausal haemorrhage:

How the study uses the data?

The study uses data from the FDA. It is based on ondansetron hydrochloride (the active ingredients of Zofran) and Zofran (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.